In fact, the use of the dual PI3K/mTOR inhibitor, dual Akt/tyrosine-kinase receptor (RTK) inhibitor, Akt inhibitor, selective inhibitor of PI3K, mTOR inhibitor, and the dual PI3K/phosphoinositide-dependent protein kinase-1 (PDK1) inhibitor in chronic and acute leukemias seem to have remarkable therapeutic effect as compared to conventional treatments [83]. This evidence concerns the gene PIK3CB and acute leukemia.